IPP Bureau
Senores Pharmaceuticals receives Philippine FDA approval for 10 products
By IPP Bureau - December 05, 2025
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Industry-academia partnership key to advancing R&D agenda, says Dr. Jitendra Singh
By IPP Bureau - December 05, 2025
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
By IPP Bureau - December 05, 2025
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Briefs: Sun Pharma and Venus Remedies
By IPP Bureau - December 04, 2025
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
By IPP Bureau - December 04, 2025
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech
By IPP Bureau - December 04, 2025
Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material
By IPP Bureau - December 04, 2025
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Philips unveils helium-free 3.0T MRI innovation at RSNA 2025
By IPP Bureau - December 04, 2025
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Zuellig Pharma launches advanced clinical trial facility in South Korea
By IPP Bureau - December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
By IPP Bureau - December 04, 2025
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Aptar acquires Brazilian pharma packaging firm Sommaplast
By IPP Bureau - December 04, 2025
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
By IPP Bureau - December 04, 2025
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules
By IPP Bureau - December 04, 2025
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
By IPP Bureau - December 04, 2025
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Eli Lilly pledges $40 million to Indiana University to expand clinical trials
By IPP Bureau - December 04, 2025
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
